Standout Papers

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Gro... 2004 2026 2011 2018 683
  1. Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors (2004)
    Dirk Strumberg, Heike Richly et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 13 from Science/Nature 66 standout
Sub-graph 1 of 20

Citing Papers

The multifaceted role of autophagy in cancer
2022 Standout
Targeting the HIF2–VEGF axis in renal cell carcinoma
2020 StandoutNobel

Works of M. E. Scheulen being referenced

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
2014
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
2004 Standout

Author Peers

Author Last Decade Papers Cites
M. E. Scheulen 2572 2258 1146 178 5.5k
Alexander Laird 1650 2646 1197 95 4.8k
Ferry A.L.M. Eskens 2813 2570 1446 159 6.2k
Annette K. Larsen 2577 3610 800 161 6.8k
Youcef M. Rustum 3668 3480 1285 243 8.1k
K. Mross 3006 2069 1013 144 5.1k
Scot C. Remick 2706 1531 1009 155 6.0k
Robert Justice 2481 2757 1657 61 6.3k
Jean‐Pierre Armand 3673 2592 2015 161 6.8k
Michelle A. Rudek 2487 3763 1011 236 7.0k
John G. Kuhn 3365 3733 1773 188 8.6k

All Works

Loading papers...

Rankless by CCL
2026